Please login to the form below

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email 

* EvaluatePharma Orphan Drug Report 2015

10th May 2017



Company Details

Lucid Group Communications Limited

+44 01494 755712

Contact Website

Burleighfield House
London Road
HP10 9RF

Latest content on this profile

Leading Edge, a Lucid Group company, strengthens its senior client services team

Lucid Group Communications Limited
From Cowgirl to Medical Writer - How did that happen?
Amy Jackson, Editorial Director, Lucid Group discusses her unlikely path into Medical Communications.
Lucid Group Communications Limited
Measures for measures
Why pharma’s marketing metrics must close the loop
Lucid Group Communications Limited
My adventure into the world of Medcomms and Lucid’s Futures Academy

Lucid Group Communications Limited
Graduation day is celebrated by Lucid’s third Futures Academy cohort

Lucid Group Communications Limited
Bluedog Launch Celebrations
Teams from all companies within the Lucid Group and Bluedog gathered to celebrate both the launch of this new partnership and Lucid Group’s twelve-year anniversary.  2019 is set to be a transformative year for Lucid Group, which, with the support of its private equity partner LDC, has big ambitions to build broader capability and reach by bringing even more magic to the mix through future acquisitions.
Lucid Group Communications Limited